API

A: Active Drug Master Files (DMF) and Certificates of Suitability (CEP) dossiers are maintained. Letters of Access (LoA) are issued promptly upon execution of a supply agreement. All regulatory updates, annual reports, and change-control notifications are communicated directly to authorized regulatory affairs contacts.

A: The synthetic route is designed to avoid high-risk reagents. When potential process-related mutagenic impurities (Alerting Structures per ICH M7) are theoretically possible, they are monitored, validated down to ppm levels using LC-MS/MS, and controlled within acceptable Threshold of Toxicological Concern (TTC) limits in the final API specification.

A: Standard commercial batch sizes range from 200 kg to 500 kg per run, with annual production capacity exceeding 50 metric tons. Campaign scheduling can be tailored to accommodate rolling forecasts from commercial partners.

A: Yes. Milling and micronization parameters are adjustable. Specific D10, D50, and D90 ranges (e.g., D90 < 10 um) can be targeted to match dissolution rate requirements and prevent segregation in powder blends

A: The API is double-bagged inside food-grade, low-density polyethylene (LDPE) bags with tamper-evident seals, then packed into fiber drums or stainless steel containers with desiccant placed between the liners. Standard storage is designated below 25°C in a dry, dark environment, backed by transport validation data covering temperature excursions.

A: All manufacturing, analytical, and site-related changes are classified under an internal Quality Management System (QMS) conforming to ICH Q7 guidelines. Major or critical changes that may impact product quality or regulatory filings are communicated to clients at least 60 to 90 days prior to implementation, allowing sufficient time for risk assessment and regulatory evaluation.